How to get sermorelin: routes ranked by what they ask
How to get sermorelin is usually written as though there were one answer, and on this site that answer has normally been discouraging. For most compounds we cover, the supervised route genuinely does not exist: nothing is approved, nothing is eligible for compounding, and a page that lists a pharmacy option is padding. This compound breaks the pattern, and a page that recycled the usual framing would be wrong.
So the ranking below is by friction rather than by preference. Each route is described by what it asks of you before it hands anything over, what you get in return, and where it fails. The route with the least friction is not the recommendation. It is simply the one with no gate on it.
We link a supplier in the lowest-friction row and earn a commission on purchases through it, as set out on our affiliate disclosure page. A ranking by friction rather than by quality is the honest way to present that, because it puts our own link at the end of the argument rather than the top.
The prescriber and the compounding pharmacy
This is the highest-friction route and the only one with a professional standing behind the preparation. It runs through a physician or another licensed prescriber, laboratory work, a clinical judgement, and a 503A compounding pharmacy that prepares the product against that prescription.
The reason it exists is specific rather than general. Sermorelin was a US medicine sold as Geref by EMD Serono. NDA 019863 covered the diagnostic product at 0.05 mg per ampoule with submissions from May 1991, and NDA 020443 covered the therapeutic version at 0.5 mg and 1 mg per vial, approved on 26 September 1997. Both are recorded as discontinued on Drugs@FDA, and the record carries the determination that this was not a safety or effectiveness action.
Section 503A allows a compounder to use a bulk substance that was a component of an FDA-approved drug product even where no USP monograph exists. Sermorelin acetate was precisely that. FDA's Category 2 bulk substances list, which flags substances presenting significant safety risks for compounding, names ibutamoren mesylate under both 503A and 503B, along with ipamorelin acetate, GHRP-2, GHRP-6 and kisspeptin-10. Sermorelin is on none of it, and never needed to be nominated.
The telehealth clinic that arranges both
A telehealth hormone or longevity clinic is the same route with the administrative work removed. It supplies the intake, orders the laboratory panel, provides the prescriber, and routes the fill to a compounding pharmacy. What you receive is a labelled compounded preparation rather than research powder.
The friction here is money and commitment rather than legwork. These practices commonly sell memberships or subscriptions, and a subscription is a different financial commitment from a one-off purchase. The thing worth reading carefully in any clinic's own material is whether an assessment can conclude that no prescription is warranted. If the answer is never, the assessment is a formality.
There is also an evidence gap to hold in view, and it does not disappear because a clinician is involved. The approved indications were paediatric growth hormone deficiency and pituitary diagnostics. PubMed holds 332 papers mentioning the compound and three with it in the title, and returns nothing at all for sermorelin together with anti-aging. ClinicalTrials.gov registers no studies naming it. The market sells adult vitality; the literature covers something else. Our page on what a local search actually finds goes through what a clinic visit involves.
The domestic research supplier
This is the lowest-friction route by a wide margin. There is no assessment, no laboratory work, no waiting for a prescription and no professional judgement. There is a listing, a price and a delivery address. That is the whole of it.
The listing we link is Ascension's Sermorelin (10 MG) at $99.99 list, $72.00 site price, and $36.00 once the code PEPTIDEDECK applies. On the 10 mg label that is $3.60 per milligram, and on the 11.31 mg that lot 38-01260229 assayed it is $3.18. Quantity tiers of three, five and ten per cent come off the list separately, and free shipping starts at $250.
The document behind it is one certificate. MZ Biolabs analysed that lot on 7 February 2026 by HPLC with ultraviolet and mass spectrometric detection, resolved four peaks, and reported 99.79% purity with 11.31 mg of material against a 10 mg label. The sequence on it converts to the canonical twenty-nine residue GHRH(1-29) amide, and the mass matches PubChem CID 16132413. What that certificate does not carry is an endotoxin test or a sterility test, and neither is a formality for a powder that gets reconstituted.
The route that is not really a route
The fourth option is an overseas marketplace listing at a per-milligram figure well under anything domestic. It reads as the lowest friction of all and is usually the highest, because the friction arrives later rather than earlier: transit time, customs, an unidentifiable seller and no practical recourse.
The specific risk with this compound is substitution. Sermorelin sits in the same marketing bucket as tesamorelin, ipamorelin and MK-677, and those are four different molecules sold as one category. Tesamorelin is a stabilised GHRH analog that is currently approved as Egrifta. Ipamorelin and MK-677 act at the ghrelin receptor rather than the GHRH receptor. A certificate with no mass detection behind it cannot rule out receiving one of them instead.
That is why the friction table below puts this row last rather than first. Cheap material with no traceable laboratory is not a saving. It is an unpriced risk that you carry alone, and unlike the research route above it, you cannot even check what arrived.
Friction, mapped against what you get
Set the four routes side by side and the pattern is uncomfortable but clear: the assurance you get tracks the friction you accept almost exactly. Nothing in this market gives you a labelled preparation and an accountable professional without an assessment attached, and nothing gives you next-day delivery with a pharmacy record.
It is worth being explicit about what we could not put in this table. We have not timed a real prescription from first appointment to filled vial, we have not audited a telehealth intake, and we do not publish a monthly cost for either supervised row, because the quotes vary too much by practice and by state for a figure we would defend. Those cells are empty on purpose. A ranking that invents plausible numbers to fill its own table is worse than one that admits where the data stops.
The honest ending is that most readers of a how to get page have already decided which end of that table they are on. Writing as though a paragraph will move somebody from the bottom row to the top is a fiction. What a page can do is make sure the person at the bottom knows exactly what is missing, and make sure the person considering the top row knows the route is genuinely available rather than theoretical.
If you are in the second group, our guide to how to get a sermorelin prescription sets out what a prescriber asks for and what a compounding pharmacy will and will not fill. If you are in the first, read the certificate before the product description, and read the assay list before the purity number.
| Route | What it asks | What you get | Where it fails |
|---|---|---|---|
| Prescriber plus 503A compounding pharmacy | Assessment, laboratory work, weeks | A labelled preparation, a pharmacist, a record | Slow, and an assessment may conclude no |
| Telehealth hormone clinic | Intake, bloodwork, usually a subscription | The same fill with the admin handled | Cost, lock-in, and marketing ahead of evidence |
| Domestic research supplier | Payment only | A vial, a lot number, one certificate | No endotoxin or sterility test on this lot |
| Overseas marketplace | Payment, then waiting | A vial, often with no traceable laboratory | Substitution risk and no recourse |
Ranked by what each route asks before it hands anything over, lowest assurance last.